ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

IBI3034

A development code.

Its studies are mostly in Glomerulonephritis, IGA, led by Innovent Biologics.

Furthest: phase 1, since Oct 8, 20261 company-led study, 1 open or runningNext primary completion: Jan 31, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Innovent Biologics11 open or runningphase 1since Oct 8, 2026Oct 8, 2026Jan 31, 2027phase 1 · NCT07886476

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 8, 2026First study: phase 1 study in Glomerulonephritis, IGAFirst studyNCT07886476 · 100 planned · China

Ahead

  1. Jan 31, 2027Primary completion: phase 1 study in Glomerulonephritis, IGANCT07886476

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07886476Glomerulonephritis, IGA · China1Not yet recruitingJan 31, 2027100

How it is read

Names in the registry

  • “IBI3034”, 1 entry

Codes read as this program: IBI3034.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.